Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi: Availability of the Pre-quarterly Results Communication

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 04:31pm EST

Availability of the Pre-quarterly Results Communication

Paris, France - January 11, 2019 - Sanofi announced today that its Pre-Quarterly Results Communication document is available on the "Investors" page of the company's website:
https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q4-results-2018

As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's fourth-quarter 2018 results will be published on February 7, 2019.


About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life



Media Relations Contact
Jack Cox
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com


Investor Relations Contact
George Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com


Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.



This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01/19SANOFI : invests 80m and extends collaboration agreement with BioNTech
AQ
01/18LEXICON PHARMACEUTICALS : Stock Trading Halted Today, FDA Advisory Committee to ..
AQ
01/18TODAY'S LOGISTICS REPORT : Rerouting for Brexit; Reeling Smartphone Suppliers; B..
DJ
01/18LEXICON PHARMACEUTICALS : Stock Trading Halted Today; FDA Advisory Committee to ..
AQ
01/17Sanofi/Lexicon Diabetes Drug Gets 8-8 Vote From FDA Panel -- Update
DJ
01/17UNBEARABLE' : European Firms Face Brexit Uncertainty -- Update
DJ
01/17Sanofi/Lexicon Diabetes Drug Gets 8-8 Vote From FDA Panel
DJ
01/17SANOFI : FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatm..
GL
01/17UNBEARABLE' : European Firms Face Brexit Uncertainty -- 2nd Update
DJ
01/17UNBEARABLE' : European Firms Face Brexit Uncertainty -- Update
DJ
More news
Financials (€)
Sales 2018 34 998 M
EBIT 2018 8 558 M
Net income 2018 5 040 M
Debt 2018 16 751 M
Yield 2018 4,22%
P/E ratio 2018 17,14
P/E ratio 2019 16,13
EV / Sales 2018 3,08x
EV / Sales 2019 2,95x
Capitalization 90 960 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 82,7 €
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-3.40%103 282
JOHNSON & JOHNSON1.27%350 508
PFIZER-2.57%246 674
NOVARTIS5.09%227 840
ROCHE HOLDING LTD.5.96%223 053
MERCK AND COMPANY-0.71%197 291